Skip to main content
. 2018 Feb 6;2018(2):CD011123. doi: 10.1002/14651858.CD011123.pub2

Carter 1975.

Study characteristics
Methods Phase III parallel‐group RCT.
Open label study.
Participants Untreated and previously treated metastatic melanoma.
Number of participants:270.
Interventions Four‐arm trial:
  • Dacarbazine 4.5 mg/kg IV days 1 to 10 (N = 48);

  • Dacarbazine 2.7 mg/kg IV days 1 to 5, lomustine 1.5 mg/kg orally day 2, and vincristine 0.027 mg/kg IV days 1, 5 every 6 weeks (N = 67);

  • Dacarbazine 2.7 mg/kg IV days 1 to 5, carmustine 2.0 mg/kg IV day 2, and vincristine 0.027 mg/kg IV days 1, 5 every 6 weeks (N = 64);

  • Dacarbazine 2.7 mg/kg IV days 1 to 5, carmustine 2.0 mg/kg IV day 2, and hydroxyurea 30 mg/kg IV days 2, 5, 9, 12, 16, 19 (N = 63).

Outcomes Progression‐free survival.
Overall survival.
Tumour response.
Toxicity.
Notes Cross‐over: not allowed.
Quality of life: not reported.
Participants with brain metastasis: included.
Median follow‐up: not available.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Quote: "Patients were randomised".
Comment: There was insufficient information to permit judgment.
Allocation concealment (selection bias) Unclear risk There was insufficient information to permit judgment.
Blinding of participants and personnel (performance bias)
All outcomes Low risk As an open label study, no blinding of participants or personnel was possible. However, we believe that in this setting (metastatic melanoma), with the treatments tested and outcomes assessed, the knowledge of which intervention was received or administered (rather than the intervention itself), could not affect the outcomes under investigation. Therefore, we judged the risk of performance bias as low.
Blinding of outcome assessment (detection bias)
All outcomes Unclear risk There was insufficient information to permit judgment.
Incomplete outcome data (attrition bias)
All outcomes Unclear risk There was insufficient information to permit judgment.
Selective reporting (reporting bias) Unclear risk There was insufficient information to permit judgment.
Other bias Unclear risk There was insufficient information to permit judgment.